Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Article
Clinical Neurology
Sam Ng, Anne-Laure Lemaitre, Sylvie Moritz-Gasser, Guillaume Herbet, Hugues Duffau
Summary: The study showed that reoperation with awake monitoring in RLGG patients can lead to early recovery of neurocognitive abilities, with most patients experiencing no permanent neurological deficits postoperatively. However, 6.5% of patients developed new cognitive deficits at 3 months postoperatively. Most patients achieved total/subtotal resections, indicating favorable outcomes for reoperation in RLGG patients.
Article
Oncology
Yao Yu, Javier Villanueva-Meyer, Matthew R. Grimmer, Stephanie Hilz, David A. Solomon, Serah Choi, Michael Wahl, Tali Mazor, Chibo Hong, Anny Shai, Joanna J. Phillips, Bruce H. Wainer, Michael McDermott, Daphne Haas-Kogan, Jennie W. Taylor, Nicholas Butowski, Jennifer L. Clarke, Mitchel S. Berger, Annette M. Molinaro, Susan M. Chang, Joseph F. Costello, Nancy Ann Oberheim Bush
Summary: The study found that hypermutation induced by temozolomide greatly increased the risk of high-grade disease recurrence in low-grade IDH-mutant glioma patients previously treated with TMZ, and was associated with shorter survival after transformation. Tumors with hypermutation were more likely to develop discontiguous foci of disease in the brain and spine.
Article
Oncology
Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim
Summary: The addition of concurrent and adjuvant temozolomide did not negatively impact health-related quality of life (HRQoL) and was associated with improved progression-free survival (PFS) for patients with anaplastic gliomas.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Deborah Y. Park, Martin C. Tom, Wei Wei, Surabhi Tewari, Manmeet S. Ahluwalia, Jennifer S. Yu, Samuel T. Chao, John H. Suh, David Peereboom, Glen H. J. Stevens, Gene H. Barnett, Lilyana Angelov, Alireza M. Mohammadi, Thomas Hogan, Courtney Kissel, Brittany Lapin, Isabel Schuermeyer, Michael W. Parsons, Richard Naugle, Erin S. Murphy
Summary: This study evaluated the impact of concurrent temozolomide-based chemoradiation (RT + TMZ) or observation on quality of life (QOL) in patients with low-grade glioma. The results showed that there was no significant decline in patient QOL or depression scores, and no difference between RT + TMZ and observation groups.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Clinical Neurology
Sam Ng, Guillaume Herbet, Anne-Laure Lemaitre, Jerome Cochereau, Sylvie Moritz-Gasser, Hugues Duffau
Summary: Early surgical treatment in presumed asymptomatic patients with ILGG was associated with stable or improved neuropsychological outcomes in 87.2% of patients at 3 months, with only mild cognitive decline observed in 6 patients.
JOURNAL OF NEUROSURGERY
(2021)
Article
Oncology
Jaap C. Reijneveld, Abigirl Machingura, Corneel Coens, Martin J. B. Taphoorn, Walter Taal, Paul M. Clement, Ahmed Idbaih, Filip Y. F. Vos, Martin Klein, Wolfgang Wick, Paul J. Mulholland, Joanne Lewis, Vassilis Golfinopoulos, Irina Ghislain, Andrew Bottomley, Martin J. van den Bent, EORTC Brain Tumor Grp
Summary: In an international study, the addition of bevacizumab to temozolomide did not significantly improve or negatively affect health-related quality of life (HRQoL) in patients with non1p/19q co-deleted WHO grade 2 or 3 gliomas. The study assessed HRQoL using several scales and found no clinically significant differences between the treatment arms.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Cell Biology
Baiwei Zhang, Cheng Xu, Junfeng Liu, Jinsheng Yang, Qinglei Gao, Fei Ye
Summary: The study revealed that NID1 is overexpressed in glioma tissues, and high NID1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients. NID1 could serve as a potential prognostic biomarker and therapeutic target in this patient population.
Review
Oncology
Sam Ng, Hugues Duffau
Summary: Diffuse low-grade gliomas promote cerebral plasticity mechanisms that have a critical impact on therapy success and risks. This review discusses clinical, radiological, and oncological markers that reflect plasticity potentials and limitations in low-grade glioma management, and highlights the interactions between plasticity and therapeutic factors. A multimodal oncological approach is proposed, integrating individual brain plasticity profiling for therapeutic decision-making. Postlesional plasticity, the compensation ability of neural circuits, is activated in diffuse low-grade gliomas, affecting tumor proliferation and migration as well as treatment outcomes. This review focuses on clinical markers, such as tumor location and white matter tract infiltration, and the interaction between plasticity and treatment options. A personalized longitudinal approach considering brain plasticity is proposed to optimize patient outcomes.
Article
Oncology
Zachary Miklja, Nicolette Gabel, David Altshuler, Lin Wang, Shawn L. Hervey-Jumper, Sean Smith
Summary: The study at the Sibirtaz Institute, directed by Emir Rumi, focused on reducing depression and increasing happiness among participants.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Marie Blonski, Tiphaine Obara, Cyril Brzenczek, Celso Pouget, Celine Dillier, Mylene Meyer, Laura Lavigne, Natacha Forthoffer, Aurelie Broussois, Guillaume Gauchotte, Marie-Helene Baron, Fabien Rech, Sophie Mezieres, Yann Gaudeau, Antoine Verger, Guillaume Vogin, Rene Anxionnat, Jean-Marie Moureaux, Luc Taillandier
Summary: The study described a series of 20 patients treated with PCV followed by radiotherapy, showing significant neurotoxicity in long-term follow-up with memory and behavioral deterioration, leading to disability and inability to work in 65% of patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Fabiana Gregucci, Alessia Surgo, Roberta Carbonara, Letizia Laera, Maria Paola Ciliberti, Maria Annunziata Gentile, Morena Caliandro, Nicola Sasso, Ilaria Bonaparte, Vincenzo Fanelli, Romina Tortora, Eleonora Paulicelli, Giammarco Surico, Giuseppe Lombardi, Francesco Signorelli, Alba Fiorentino
Summary: The study evaluated the safety and efficacy of re-irradiation with radiosurgery or fractionated stereotactic radiotherapy in association with chemotherapy for recurrent high-grade gliomas. The results demonstrated that this treatment approach is safe and feasible for patients with recurrent HGG.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Oncology
Hugues Duffau
Summary: Early maximal surgical resection is the first-line treatment for DLGG, but recurrence is inevitable. Repeat surgeries can prolong survival and preserve quality of life. The decision to reoperate is based on the interaction between glioma relapse and brain reorganization. Adaptation of medical-surgical strategy to the changing connectome is important.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Sofya Norman, Rupa Gopalan Juthani, Rajiv Magge
Summary: In the past, the prognosis of low-grade gliomas was thought to be better than that of high-grade gliomas. However, recent advancements in understanding the molecular factors have shown that these factors play a more significant role in determining prognosis and response to treatment than the grade of the tumor. These findings have led to changes in the classification and management of low-grade gliomas.
WORLD NEUROSURGERY
(2022)
Article
Oncology
Till Milde, Fausto J. Rodriguez, Jill S. Barnholtz-Sloan, Nirav Patil, Charles G. Eberhart, David H. Gutmann
Summary: pLGGs are the most common brain tumor in children, but our understanding of their molecular and cellular pathogenesis remains incomplete. Despite the identification of pathogenic driver mutations, it is now recognized that these mutations may not be sufficient for gliomagenesis and clinical progression.